Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Research & Development (2020 - 2025)

Silence Therapeutics' Research & Development history spans 6 years, with the latest figure at $27.7 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 31.04% to $27.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73.2 million, a 7.79% increase, with the full-year FY2025 number at $67.8 million, changed 0.19% from a year prior.
  • Research & Development hit $27.7 million in Q4 2025 for Silence Therapeutics, up from $13.1 million in the prior quarter.
  • Over the last five years, Research & Development for SLN hit a ceiling of $97.0 million in Q4 2023 and a floor of -$10.3 billion in Q1 2021.
  • Historically, Research & Development has averaged -$499.9 million across 5 years, with a median of $7.0 million in 2024.
  • Biggest five-year swings in Research & Development: crashed 99.59% in 2021 and later skyrocketed 220.54% in 2024.
  • Tracing SLN's Research & Development over 5 years: stood at $73.2 million in 2021, then grew by 0.64% to $73.7 million in 2022, then soared by 31.6% to $97.0 million in 2023, then tumbled by 58.57% to $40.2 million in 2024, then crashed by 31.04% to $27.7 million in 2025.
  • Business Quant data shows Research & Development for SLN at $27.7 million in Q4 2025, $13.1 million in Q3 2025, and $17.6 million in Q2 2025.